natgillin/translations-raw huggingface dataset:
Ferriprox and deferoxamine were equivalent in promoting a net stabilization or reduction of body iron load, despite the continuous transfusional iron administration in those patients (no difference in proportion of patients with a negative trend in serum ferritin between the two treatment groups by regression analysis; p >0.05). 
Ferriprox i deferoksamin bili su jednaki u poboljšanju stabilizacije ili redukcije opterećenja tijela željezom unatoč kontinuiranoj primjeni željeza u transfuzijama u ovih bolesnika (nije bilo razlike u udjelu bolesnika s negativnim trendom feritina u serumu između dviju liječenih skupina dobivene regresijskom analizom; p >0,05).
There was an improvement in cardiac T2* of more than 3 ms in patients treated with Ferriprox compared with a change of about 1 ms in patients treated with deferoxamine. 
Srčana vrijednost T2* poboljšala se za više od 3 ms u bolesnika liječenih Ferriproxom u usporedbi s promjenom od oko 1 ms u bolesnika liječenih deferoksaminom.
Studies LA16-0102, LA-01 and LA08-9701 compared the efficacy of Ferriprox with that of deferoxamine in controlling serum ferritin in transfusion-dependent thalassaemia patients. 
Ispitivanja LA16-0102, LA-01 i LA08-9701 uspoređivala su djelotvornost Ferriproxa s deferoksaminom za kontrolu feritina u serumu u bolesnika s talasemijom ovisnom o transfuziji.
If you experience nausea or vomiting, it may help to take your Ferriprox with some food. 
Ako osjetite mučninu ili povraćate, od pomoći može biti uzimati Ferriprox s nešto hrane.
In these patients careful monitoring of liver histology is recommended. 
ovih se bolesnika preporučuje pažljivo praćenje histoloških promjena u jetri.
The change from weekly ANC monitoring to at the time of transfusion visits after 12 months of Ferriprox therapy, should be considered on an individual patient basis, according to the physician's assessment of the patient's understanding of the risk minimization measures required during therapy (see section 4.4 below). 
Promjenu od tjednog praćenja ABN-a na praćenje ABN-a tijekom posjeta radi transfuzije, nakon što je prošlo razdoblje od 12 mjeseci liječenja Ferriproxom, treba razmotriti za svakog bolesnika pojedinačno na temelju liječnikove ocjene bolesnikovog razumijevanja mjera minimizacije rizika koje je potrebno provoditi tijekom liječenja (vidjeti dio 4.4 ispod).
Fertility No effects on fertility or early embryonic development were noted in animals (see section 5.3). 
Nisu primijećeni učinci na plodnost ili rani embrionalni razvoj u životinja (vidjeti dio 5.3).
After starting Ferriprox therapy, it is recommended that serum ferritin concentrations, or other indicators of body iron load, be monitored every two to three months to assess the long-term effectiveness of the chelation regimen in controlling the body iron load. 
Nakon započinjanja terapije Ferriproxom preporučuje se praćenje koncentracija feritina u serumu, ili drugih pokazatelja opterećenja tijela željezom, svaka dva do tri mjeseca, radi procjene dugotrajne učinkovitosti režima kelacije u svrhu kontrole opterećenja tijela željezom.
BOTTLE OF 50 TABLETS 
BOCA OD 50 TABLETA
− increase in liver enzymes 
Pretrage povišeni jetreni enzimi
Data from the published literature on iron balance studies in patients with thalassaemia major show that the use of Ferriprox concurrently with deferoxamine (coadministration of both chelators during the same day, either simultaneously or sequentially, e.g., Ferriprox during the day and deferoxamine during the night), promotes greater iron excretion than either drug alone. 
Podaci iz objavljene literature o ispitivanjima ravnoteže željeza kod bolesnika s talasemijom major pokazuju da primjena Ferriproxa istodobno s deferoksaminom (istodobna primjena oba kelatora istog dana, bilo simultano ili jedan iza drugog, npr. Ferriprox tijekom dana a deferoksamin tijekom noći) potiče veće izlučivanje željeza nego bilo koji od lijekova primijenjen samostalno.
Should any evidence of infection develop concurrently with the neutropenia, the appropriate cultures and diagnostic procedures should be performed and an appropriate therapeutic regimen instituted. 
Ako se istodobno s neutropenijom razviju znakovi postojanja infekcije, potrebno je učiniti odgovarajuće mikrobiološke pretrage i dijagnostičke postupke, te uspostaviti odgovarajući terapijski režim.
The higher rate of “Cardiac disorders" reported during combination therapy than monotherapy was possibly due to the higher incidence of pre-existing cardiac disorders in patients who received combination therapy. 
Veća stopa "srčanih poremećaja" prijavljenih za vrijeme kombinirane terapije nego za vrijeme monoterapije je možda uzrokovana većom incidencijom postojećih srčanih poremećaja kod bolesnika koji su primali kombiniranu terapiju.
No prenatal and postnatal reproductive studies have been conducted in animals. 
Nisu provedena prenatalna i postnatalna reproduktivna ispitivanja na životinjama.
MONITORING YOUR WHITE BLOOD CELL COUNT WITH FERRIPROX 
PRATITE BROJ SVOJIH BIJELIH KRVNIH STANICA DOK UZIMATE FERRIPROX
A serious adverse event of acute liver and renal injury was seen in one subject with moderate hepatic impairment. 
Ozbiljan štetan događaj akutnog oštećenja jetre i bubrega primijećen je u jednog ispitanika s umjerenim oštećenjem funkcije jetre.
Peak serum concentrations of the glucuronide occur 2 to 3 hours after administration of deferiprone. 
Vršne koncentracije glukuronida u serumu nastupaju 2 do 3 sata nakon primjene deferiprona.
Combination therapy with deferoxamine is not recommended when monotherapy with either chelator is adequate or when serum ferritin falls below 500 µg/l. 
Kombinirana terapija s deferoksaminom ne preporučuje se ako je monoterapija s jednim od kelatora odgovarajuća ili ako serumski feritin padne ispod 500 µg/l.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 25 August 1999 
Datum prvog odobrenja: 25. kolovoza 1999.
Obtain a complete blood cell (CBC) count, with a white blood cell (WBC) count, corrected for the presence of nucleated red blood cells, a neutrophil count, and a platelet count immediately upon diagnosing the event and then repeat daily. 
Učinite kompletnu krvnu sliku (KKS), s brojem leukocita, korigiranim za prisutnost eritrocita s jezgrom, brojem neutrofila i brojem trombocita odmah nakon dijagnosticiranja događaja, a zatim je ponavljajte svakog dana.
In the event of agranulocytosis, rechallenge is contraindicated. 
U slučaju agranulocitoze ponovna primjena lijeka je kontraindicirana.
The most common findings in non-iron-loaded animals at doses of 100 mg/kg/day and above were hematologic effects such as bone marrow hypocellularity, and decreased WBC, RBC and/or platelet counts in peripheral blood. 
Najčešći nalazi u željezom ne opterećenih životinja pri dozama od 100 mg/kg/dan i više bili su hematološki učinci poput hipocelularnosti koštane srži i pada broja leukocita, eritrocita i/ili trombocita u perifernoj krvi.
Data from the published literature are consistent with the results from the Apotex studies, demonstrating less heart disease and/or increased survival in Ferriprox-treated patients than in those treated with deferoxamine. 
Podaci objavljeni u literaturi sukladni su rezultatima iz Apotex ispitivanja, pokazujući manje bolesti srca i/ili povećano preživljenje bolesnika liječenih Ferriproxom nego onih liječenih deferoksaminom.
− if you have a history of repeated episodes of neutropenia (low white blood cell (neutrophil) 
− ako ste u povijesti bolesti imali ponavljane epizode neutropenije (sniženi broj bijelih krvnih stanica (neutrofila)).
Common side effects (may affect up to 1 in 10 people): - low white blood cell count (agranulocytosis and neutropenia) - headache - diarrhoea - increase in liver enzymes - fatigue - increase in appetite 
Česte nuspojave (mogu se pojaviti kod do 1 na 10 ljudi): - nizak broj leukocita (agranulocitoza i neutropenija) - glavobolja - proljev - porast jetrenih enzima - umor
The MAH should provide a patient/carer reminder card in each pack, the text of which is included in the Package Leaflet. 
Nositelj odobrenja u svakom pakiranju mora osigurati karticu s podsjetnikom za bolesnika/njegovatelja, čiji tekst je uključen i u uputu o lijeku.
Of patients with cardiac dysfunction at first assessment, none treated with deferiprone compared with four (33%) treated with deferoxamine had worsening of their cardiac status (p=0.245). 
Od bolesnika s disfunkcijom srca na prvoj procjeni kod niti jednog koji je liječen deferipronom, u usporedbi s četiri (33%) liječenih deferoksaminom, nije imalo pogoršanje njegovog srčanog statusa (p=0,245).
It is packaged in bottles of 250 ml or 500 ml. 
Pakirana je u bocama od 250 ml ili
Fatalities and life-threatening situations (caused by agranulocytosis) have been reported with deferiprone in combination with deferoxamine. 
Prijavljeni su smrtni slučajevi i situacije opasne po život (uzrokovane agranulocitozom) kada se deferipron koristio u kombinaciji s deferoksaminom.
If you forget to take Ferriprox 
Ako ste zaboravili uzeti Ferriprox
There is a small chance that you may develop agranulocytosis (very low white blood cell count) while taking Ferriprox, which may lead to a serious infection. 
Postoji mala mogućnost da se kod Vas, dok uzimate Ferriprox, razvije agranulocitoza (vrlo nizak broj bijelih krvnih stanica), što može dovesti do ozbiljne infekcije.
Following randomization, 32 patients received deferoxamine (34.9 mg/kg/day for 5 days/week) and Ferriprox (75 mg/kg/day) and 33 patients received deferoxamine monotherapy (43.4 mg/kg/day for 5 days/week). 
32 bolesnika primala su deferoksamin (34,9 mg/kg/dan tijekom 5 dana u tjednu) i Ferriprox (75 mg/kg/dan), a 33 bolesnika primala su monoterapiju deferoksaminom (43,4 mg/kg/dan tijekom 5 dana u tjednu).
BOTTLE OF 100 TABLETS 
BOCA OD 100 TABLETA
The incidences of “Musculoskeletal and connective tissue disorders” and "Renal and urinary disorders" were lower during combination therapy than monotherapy, whereas the incidence of “Cardiac disorders" was higher during combination therapy than monotherapy. 
Incidencije "poremećaja mišićno-koštanog sustava i vezivnog tkiva" te "poremećaja bubrega i mokraćnog sustava" bile su manje za vrijeme kombinirane terapije nego za vrijeme monoterapije, dok je incidencija "srčanih poremećaja" bila veća za vrijeme kombinirane terapije nego za vrijeme monoterapije.
This condition, known as severe neutropenia or agranulocytosis, has occurred in 1 to 2 out of 100 people who have taken Ferriprox in clinical studies. 
Ovo stanje, poznato kao teška neutropenija ili agranulocitoza, javilo se u 1 do 2 na 100 ljudi koji su uzimali Ferriprox u kliničkim ispitivanjima.
Ferriprox can be taken with or without food; however, you may find it easier to remember to take Ferriprox if you take it with your meals. 
Ferriprox se može uzimati s hranom ili bez nje; međutim, možda će Vam ipak biti lakše zapamtiti da uzmete Ferriprox ako ga uzimate s obrocima.
Each pack contains one bottle of 250 ml or 500 ml oral solution. 
Svako pakovanje sadrži jednu bocu od 250 ml ili 500 ml oralne otopine.
Iron overload causes concentration-dependent MRI T2* signal loss, thus, increased myocardial iron reduces myocardial MRI T2* values. 
Preopterećenje željezom uzrokuje gubitak signala MR T2* ovisnog o koncentraciji, stoga povišeno željezo u miokardu smanjuje MR T2* vrijednosti miokarda.
Subjects were categorized into 3 groups based on the Child-Pugh classification score: healthy volunteers, mild hepatic impairment (Class A: 5- 6 points), and moderate hepatic impairment (Class B: 7- 9 points). 
Ispitanici su, na temelju bodova prema Child-Pugh klasifikaciji, bili podijeljeni u 3 skupine: zdravi dobrovoljci, ispitanici s blagim oštećenjem funkcije jetre (stadij A: 5 - 6 bodova) i ispitanici s umjerenim oštećenjem funkcije jetre (stadij B: 7 - 9 bodova).
Episodes of diarrhoea, mostly mild and transient, have been reported in patients treated with deferiprone. 
Epizode proljeva, većinom blagog i prolaznog, prijavljene su u bolesnika liječenih deferipronom.
Deferiprone was teratogenic and embryotoxic in reproductive studies in non-iron-loaded pregnant rats and rabbits at doses at least as low as 25 mg/kg/day. 
U reproduktivnim ispitivanjima deferipron je bio teratogen i embriotoksičan u željezom ne opterećenih skotnih ženki štakora i kunića u dozama niskim najmanje od 25 mg/kg/dan.
Data from the pooled safety database from clinical trials (1343 patient-years exposure to Ferriprox monotherapy and 244 patient-years exposure to Ferriprox and deferoxamine) showed statistically significant (p<0.05) differences in the incidence of adverse reactions based on System Organ Class for “Cardiac disorders", "Musculoskeletal and connective tissue disorders” and "Renal and urinary disorders". 
Podaci iz objedinjene baze podataka o sigurnosti primjene dobivenih iz kliničkih ispitivanja (1343 bolesnik-godina izloženosti monoterapiji Ferriproxom i 244 bolesnik-godina izloženosti Ferriproxu i deferoksaminu) pokazali su statistički značajne (p<0,05) razlike u incidenciji nuspojava koje se temelje na klasifikaciji organskih sustava za "srčane poremećaje", "poremećaje mišićnokoštanog sustava i vezivnog tkiva" te "poremećaja bubrega i mokraćnog sustava".
Ferriprox is packaged in bottles of 50 tablets. 
Ferriprox je pakiran u bocama od 50 tableta.
Deferiprone is usually given as 25 mg/kg body weight, orally, three times a day for a total daily dose of 75 mg/kg body weight. 
Doziranje Deferipron se obično daje u dozi od 25 mg/kg tjelesne težine, peroralno, tri puta na dan, do ukupne dnevne doze od 75 mg/kg tjelesne težine.
A randomized, placebo-controlled, double-blind trial evaluated the effect of concurrent therapy with Ferriprox and deferoxamine in patients with thalassaemia major, who previously received the standard chelation monotherapy with subcutaneous deferoxamine and had mild to moderate cardiac iron loading (myocardial T2* from 8 to 20 ms). 
Randomizirano, placebom kontrolirano, dvostruko slijepo ispitivanje procijenilo je učinak istodobne terapije s Ferriproxom i deferoksaminom kod bolesnika s talasemijom major, koji su prethodno primali standardnu kelacijsku monoterapiju sa supkutano primijenjenim deferoksaminom i imali su blago do umjereno srčano opterećenje željezom (T2* miokarda od 8 do 20 ms).
− the most serious side effect that may occur while taking Ferriprox is a very low white blood cell (neutrophil) count. 
− najozbiljnija nuspojava koje se može dogoditi dok uzimate Ferriprox je vrlo nizak broj bijelih krvnih stanica (neutrofila).
Ferriprox is packaged in bottles of 100 tablets. 
Ferriprox je pakiran u bocama od 100 tableta.
Renal or hepatic impairment and liver fibrosis 
Oštećenje funkcije bubrega ili jetre i fibroza jetre
PHARMACEUTICAL FORM AND CONTENTS 100 film-coated tablets 
OBLIK I SADRŽAJ 100 filmom obloženih tableta
Study LA16-0102 compared the efficacy of Ferriprox with that of deferoxamine in decreasing cardiac iron overload and in improving cardiac function (as measured by LVEF) in transfusion-dependent thalassaemia patients. 
Ispitivanje LA16-0102 uspoređivalo je djelotvornost Ferriproxa s onom deferoksamina u smanjivanju opterećenja srca željezom i poboljšanju funkcije srca (mjerenjem LVEF) u bolesnika s talasemijom ovisnom o transfuziji.
Atrophy of the thymus, lymphoid tissues, and testis, and hypertrophy of the adrenals, were reported at doses of 100 mg/kg/day or greater in non-iron-loaded animals. 
Atrofija timusa, limfoidnog tkiva i testisa, te hipertrofija nadbubrežnih žlijezda prijavljeni su pri dozama od 100 mg/kg/dan ili višim u životinja ne opterećenih željezom.
Deferiprone use should be discontinued if neurological disorders are observed (see sections 4.8 and 
Treba prekinuti primjenu deferiprona ako se opaze neurološki poremećaji (vidjeti dijelove 4.8 i 4.9).
Events of joint pain and swelling ranged from mild pain in one or more joints to severe disability. 
Pojava bolova u zglobovima i oticanje kretala se od blage boli u jednom ili više zglobova do teške onesposobljenosti.
There are no data available on the use of deferiprone in patients with end stage renal disease or severe hepatic impairment (see section 5.2). 
Nema dostupnih podataka o primjeni deferiprona u bolesnika sa završnim stadijem bolesti bubrega ili teškim oštećenjem funkcije jetre (vidjeti dio 5.2).
BOTTLES OF 250 ML AND 500 ML ORAL SOLUTION 
BOCE OD 250 ML I 500 ML ORALNE OTOPINE
A positive correlation between MRI T2* values and cardiac function (as measured by Left Ventricular Ejection Fraction (LVEF)) has been documented. 
Dokumentirana je pozitivna korelacija između MR T2* vrijednost i funkcije srca (mjerenjem ejekcijske frakcije lijevog ventrikula
Dose per kilogram body weight should be calculated to the nearest half tablet. 
Dozu po kilogramu tjelesne težine treba izračunati do najbliže doze koja se postiže primjenom polovice tablete.
A magnetic resonance imaging (MRI) method, T2*, was also used to quantify myocardial iron load. 
Također je korištena i metoda magnetske rezonancije (MR), T2*, za kvantitativno određivanje opterećenja miokarda željezom.
Please refer to the patient/carer reminder card attached to this leaflet. 
Molimo pogledajte u karticu s podsjetnikom za bolesnika/njegovatelja pričvršćenu za ovu uputu.
To obtain a dose of about 75 mg/kg/day, use the number of tablets suggested in the following tables for the body weight of the patient. 
Za određivanje doze od oko 75 mg/kg/dan, koristiti preporučeni broj tableta naveden u sljedećoj tablicama prema tjelesnoj težini bolesnika.
Careful monitoring of cardiac events in patients on combination therapy is warranted (see section 4.4). 
Savjetuje se pažljivo motrenje srčanih događaja kod bolesnika koji primaju kombiniranu terapiju (vidjeti dio 4.4).
Hypromellose 2910 USP/EP 
Ovojnica hipromeloza 2910 USP/EP hidroksipropilceluloza makrogol titanijev dioksid
Patients should be aware to contact their physician if they experience any symptoms indicative of infection (such as fever, sore throat and flu-like symptoms). 
Bolesnike treba upozoriti da se jave svom liječniku ako primijete bilo koji simptom koji može upućivati na infekciju (kao što je vrućica, grlobolja ili simptomi nalik gripi).
It is recommended that following recovery from neutropenia, weekly CBC, WBC, neutrophil and platelet counts continue to be obtained for three consecutive weeks, to ensure that the patient recovers fully. 
Nakon oporavka neutropenije preporučuje se kontrola KKS, broja leukocita, neutrofila i trombocita tijekom tri uzastopna tjedna kako bi se sa sigurnošću utvrdilo da se bolesnik u potpunosti oporavio.
Newly diagnosed cardiac dysfunction occurred in 13 (20.6%) deferoxamine-treated patients and in 2 (4.3%) Ferriprox-treated patients who were cardiac disease-free at the first assessment (p=0.013). 
Novodijagnosticirana disfunkcija srca utvrđena je u 13 (20,6%) bolesnika liječenih deferoksaminom i u 2 (4,3%) bolesnika liječena Ferriproxom, a koji nisu imali bolest srca kod prve procjene (p=0,013).
Deferiprone has been shown to cause neutropenia, including agranulocytosis (see section 4.8 ‘Description of selected adverse reactions'). 
Pokazalo se da deferipron uzrokuje neutropeniju, uključujući i agranulocitozu (vidjeti dio 4.8,
Deferiprone-3-O-glucuronide AUC was decreased by 10% and Cmax by 20% in mildly and moderately impaired subjects compared with healthy volunteers. 
Vrijednost AUC-a deferipron-3-O-glukuronida smanjila se za 10%, a Cmax-a za 20% u ispitanika s blagim i umjerenim oštećenjem funkcije jetre u usporedbi sa zdravim dobrovoljcima.
Ferriprox oral solution contains the colouring agent Sunset Yellow (E110) which may cause allergic reactions. 
Ferriprox oralna otopina sadrži bojilo Sunset Yellow (E110) koje može uzrokovati alergijske reakcije.
Deferiprone therapy should be initiated and maintained by a physician experienced in the treatment of patients with thalassaemia. 
4.2 Doziranje i način primjene Terapiju deferipronom treba započeti i provoditi liječnik iskusan u liječenju bolesnika s talasemijom.
Ferriprox oral solution contains Sunset Yellow (E110) Sunset Yellow (E110) is a colouring agent which may cause allergic reactions. 
Ferriprox oralna otopina sadrži Sunset Yellow (E110) Sunset Yellow (E110) je bojilo koje može uzrokovati alergijske reakcije.
At the same time point, LVEF had increased from baseline by 3.07 ± 3.58 absolute units (%) in the Ferriprox group and by 0.32 ± 3.38 absolute units (%) in the deferoxamine group (difference between groups; p=0.003). 
3,07 ± 3,58 apsolutnih jedinica (%) u skupini koja je primala Ferriprox i za 0,32 ± 3,38 apsolutnih jedinica (%) u skupini koja je primala deferoksamin (razlika između skupina; p=0,003).
Very common side effects (may affect more than 1 in 10 people): 
Vrlo česte nuspojave (mogu se pojaviti kod više od 1 na 10 ljudi): - bol u trbuhu
In females, an effect on the oestrous cycle delayed time to confirmed mating at all doses tested. 
Za potvrdu parenja kod ženki je učinjen test odgođenog ciklusa estrusa pri svim dozama.
The maximum difference between the LS means of the therapeutic dose and placebo was 3.01 ms (95% one-sided UCL: 5.01 ms), and between the LS means of the supratherapeutic dose and placebo was 5.23 ms (95% one-sided UCL: 7.19 ms). 
Maksimalna razlika između LS srednjih vrijednosti terapijske doze i placeba bila je 3,01 ms (gornja granica jednostranog 95%-tnog intervala pouzdanosti: 5,01 ms), a između LS srednjih vrijednosti supraterapijske doze i placeba bila je 5,23 ms (gornja granica jednostranog 95%-tnog intervala pouzdanosti: 7,19 ms).
Clinical studies have demonstrated that Ferriprox is effective in promoting iron excretion and that a dose of 25 mg/kg three times per day can prevent the progression of iron accumulation as assessed by serum ferritin, in patients with transfusion-dependent thalassaemia. 
Klinička ispitivanja pokazala su da je Ferriprox učinkovit u poboljšanju izlučivanja željeza, i da u dozi od 25 mg/kg tri puta na dan može spriječiti progresiju akumulacije željeza, a što je dokazivo mjerenjem feritina u serumu, u bolesnika s talasemijom ovisnom o transfuziji.
Sunset Yellow (E110) 
Sunset Yellow (E110) sukraloza (E955)
Amber polyethylene terephthalate (PET) bottles with child resistant closure (polypropylene), and a graduated measuring cup (polypropylene). 
Smeđe boce od polietilentereftalata (PET) sa sigurnosnim zatvaračem za djecu (polipropilen), i graduiranom odmjernom čašom (polipropilen).
Number of 1000 mg tablets* Morning 
Broj tableta od 1000 mg*
HIV positive or other immunocompromised patients No data are available on the use of deferiprone in HIV positive or in other immunocompromised patients. 
Nema dostupnih podataka o primjeni deferiprona u HIV pozitivnih ili drugih imunokompromitiranih bolesnika.
If the patient develops an infection while on deferiprone, therapy should be immediately interrupted, and an ANC obtained without delay. 
Ako bolesnik tijekom liječenja deferipronom razvije infekciju, liječenje treba odmah prekinuti i bez odgađanja provjeriti apsolutni broj neutrofila.
For patients whose Ferriprox has not been interrupted during the first year of therapy due to any decrease in the neutrophil count, the frequency of ANC monitoring may be extended to the patient's blood transfusion interval (every 2-4 weeks) after one year of deferiprone therapy. 
Nakon godinu dana liječenja deferipronom, u bolesnika u kojih liječenje Ferriproxom tijekom te prve godine liječenja nije bilo prekidano zbog bilo kakvog smanjenja broja neutrofila, učestalost kontroliranja ABN-a može se produljiti na interval u kojem bolesnik prima transfuzije krvi (svaka 2-4 tjedna).
Deferiprone AUCs did not differ between treatment groups, but Cmax was decreased by 20% in mildly or moderately hepatically impaired subjects compared with healthy volunteers. 
Vrijednosti AUC-a deferiprona nisu se razlikovale unutar liječenih skupina, ali Cmax je bio smanjen za 20% u ispitanika s blagim i umjerenim oštećenjem funkcije jetre u usporedbi sa zdravim dobrovoljcima.
Provide this card to your doctor if you develop infection symptoms such as a fever, sore throat or flu-like symptoms. 
Pokažite tu karticu svom liječniku ako razvijete simptome infekcije kao što su vrućica, grlobolja ili simptomi nalik gripi.